Your browser doesn't support javascript.
loading
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng, David H; Kundu, Samrat T; Fradette, Jared J; Diao, Lixia; Tong, Pan; Byers, Lauren A; Wang, Jing; Canales, Jaime Rodriguez; Villalobos, Pamela A; Mino, Barbara; Yang, Yanan; Minelli, Rosalba; Peoples, Michael D; Bristow, Christopher A; Heffernan, Timothy P; Carugo, Alessandro; Wistuba, Ignacio I; Gibbons, Don L.
Afiliação
  • Peng DH; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kundu ST; University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
  • Fradette JJ; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Diao L; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Tong P; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Byers LA; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Wang J; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Canales JR; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Villalobos PA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Mino B; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Yang Y; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Minelli R; Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine and Department of Biochemistry and Molecular Biology, Cancer Center and College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Peoples MD; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Bristow CA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Heffernan TP; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Carugo A; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Wistuba II; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Gibbons DL; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sci Transl Med ; 11(483)2019 03 13.
Article em En | MEDLINE | ID: mdl-30867319
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Receptores de Interleucina-17 / Homeobox 1 de Ligação a E-box em Dedo de Zinco / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Quinases de Proteína Quinase Ativadas por Mitógeno / Inibidores de Proteínas Quinases / Receptores de Interleucina-17 / Homeobox 1 de Ligação a E-box em Dedo de Zinco / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article